⌘K

Home/Filings/4/0001415889-25-017696

4//SEC Filing

Duncan Barbara Gayle 4

Accession 0001415889-25-017696

CIK 0001636651other

View on SEC.gov Company Profile

Filed

Jun 17, 8:00 PM ET

Accepted

Jun 18, 4:45 PM ET

Size

5.4 KB

Accession

0001415889-25-017696

Insider Transaction Report

Form 4

Period: 2025-02-20

Ovid Therapeutics Inc.OVID

Duncan Barbara Gayle

Director

Transactions

Award
Stock Option (right to buy)
2025-02-20+45,000→ 45,000 total
Exercise: $0.57Exp: 2035-02-19→ Common Stock (45,000 underlying)

Footnotes (1)

[F1]The option will vest in full on February 20, 2026, subject to the Reporting Person's continuous service through such vesting date.

Documents

1 file

4
form4-06182025_040603.xmlPrimary

Issuer

Ovid Therapeutics Inc.

CIK 0001636651

Entity typeother

Related Parties

1

filerCIK 0001353128

Filing Metadata

Form type: 4
Filed: Jun 17, 8:00 PM ET
Accepted: Jun 18, 4:45 PM ET
Size: 5.4 KB

View on SEC.gov